Skip to content

Proto Labs PRLB Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount

Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount at other companies

AbCellera Biologics Inc. logo
AbCellera Biologics Inc.ABCL
$1.5M-27.0%
CarGurus, Inc. logo
CarGurus, Inc.CARG
$980.25K
ESN
Essent GroupESNT
$79K-61.8%
Vertex, Inc. logo
Vertex, Inc.VERX
$1.13M-8.4%
Bicara Therapeutics logo
Bicara TherapeuticsBCAX
$844.25K
BioCryst Pharmaceuticals logo
BioCryst PharmaceuticalsBCRX
$330.75K-25.0%

Other financials

Income statement

See full
Revenue$139.3M+10.4%
Gross profit$63.6M+14.2%
Operating income$9.8M+117%
Net income$8.1M+125%
EPS (diluted)$0.33+120%

Balance sheet

See full
Cash & equivalents$124.0M+49.9%
Total debt$2.6M-16.6%
Total equity$683.1M+4.0%
Total assets$778.6M+5.6%

Cash flow

See full
Operating cash flow$17.5M-4.6%
CapEx$3.5M+181%
Free cash flow$14.0M-18.2%

Valuation

See full
Market cap$1.9B+59.7%
Enterprise value$1.78B+60.4%
P/E73.7×-3.9×
P/S3.5×+1.1×

Profitability

See full
Gross margin44.9%+0.5pp
Operating margin5.6%+1.7pp
Net margin4.7%+1.6pp
FCF margin10.4%-3.1pp

Returns & leverage

See full
Return on equity3.8%+1.6pp
Debt / equity0.0×
Current ratio3.5×+0.4×

Where this comes from

Reported directly by Proto Labs in its filing.

Tagged under the XBRL concept us-gaap:IncomeTaxReconciliationTaxCreditsResearch.

The official record: Proto Labs’s 10-K, filed February 20, 2026, on SEC EDGAR. View the filing →

Ask your AI about Proto Labs's effective income tax rate reconciliation, tax credit, research, amount.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Proto Labs's effective income tax rate reconciliation, tax credit, research, amount?
Proto Labs (PRLB) reported effective income tax rate reconciliation, tax credit, research, amount of $136.75K in Q4 2025.
What does effective income tax rate reconciliation, tax credit, research, amount mean?
Quantifies the specific tax credits claimed by the company for qualified research and development expenditures. This metric directly reduces the total income tax liability and reflects the company's investment in innovation. It is a vital indicator for investors to assess the tax benefits derived from R&D activities.